How Sen-Jam Is Building a Portfolio of Inflammation Drugs

In this episode of Inside Startup Investing, Chris Lustrino speaks with Jim Iversen, CEO of Sen-Jam Pharmaceutical, about building a platform of therapeutics targeting inflammation across multiple diseases. (00:00–01:28) The company is advancing a pipeline of drugs addressing conditions like COVID, alcohol-related inflammation, and arthritis, with multiple Phase 2 trials completed. (01:28–02:27) Jim explains how drug development works—from preclinical research to Phase 1 (safety), Phase 2 (efficacy), and Phase 3 (confirmatory trials). (04:14–06:05) They explore how Sen-Jam uses AI and over one million data points to validate its platform and identify new drug opportunities. (08:32–09:30) The discussion also covers how the company allocates resources across its pipeline and its strategy to license drugs after Phase 2 rather than fully commercialize them. (13:10–14:32) Finally, Jim breaks down the economics of drug licensing, potential valuation inflection points, and how investors can think about returns in biotech. (19:31–21:58)